Embattled Canadian drugmaker Valeant Pharmaceuticals may have to restate its earnings results, The Wall Street Journal reports, citing unnamed sources.
The stock was last trading down more than 10% in the late session at around $68 per share.
On Monday, the stock had fallen $9.08, or -10.68%, to close at $75.91 per share.
Valeant, which had been a hedge fund darling, has collapsed since late 2015 because of scrutiny in Washington, DC, over drug-price increases and accusations from a short seller.
In October, Andrew Left, founder of California-based short-selling firm Citron Research, issued a report asking if the company was running an Enron-like fraud. The Citron report focused on Valeant’s relationship with Philidor, a specialty pharmacy. Citron accused Valeant of using Philidor to book “phantom sales.”
The Canadian pharma giant denied any wrongdoing and soon after severed ties with Philidor.
Valeant also put together an ad hoc committee of its board to review the allegations related to the company’s relationship with Philidor.
As reported by Business Insider